Lab Sciences
Top stories summarized by our editors
7/12/2018

UK researchers found Ebola survivors from Sierra Leone had lingering psychiatric and neurological problems, including depression, anxiety, debilitating migraines, nerve pain and strokes. The findings, based on more than 300 Ebola survivors, were published in the journal Emerging Infectious Diseases.

More Summaries:
Ebola, migraines
7/12/2018

GlaxoSmithKline's investigational drug tafenoquine was found to be generally safe, effective and well-tolerated among malaria patients 16 and older, with data indicating the regimen induced a statistically significant treatment effect for Plasmodium vivax malaria, based on briefing documents the FDA disclosed before an advisory committee meeting. However, FDA researchers did note some concerns regarding the drug's safety in patients with anemia.

More Summaries:
vivax malaria, FDA, GlaxoSmithKline
7/11/2018

A seven-year international study that evaluated contemporary protease inhibitors' contribution to cardiovascular disease risk in treatment-naive adults with HIV found that Janssen's Prezista, or darunavir, was linked to progressively increasing risk of CVD compared to Bristol-Myers Squibb's Reyataz, or atazanavir. The findings, consisting of data from 49,709 participants in 11 cohorts in the US, Australia and Europe, were reported in the journal The Lancet HIV.

Full Story:
MD Magazine online
7/11/2018

Researchers assessed 200 older male patients, ages 54 to 73, with moderate to severe hemophilia to establish the prevalence of cardiovascular disease and risk factors. Findings revealed that cardiovascular disease risk factors were common in this group, with nearly a third being obese, 50% of the group having dyslipidemia and hypertension, and only 36% of hypertensive patients taking antihypertensive medication, according to the study in the journal Blood Advances.

Full Story:
Hemophilia News Today
More Summaries:
dyslipidemia
7/11/2018

American Renal Associates has entered a three-year network agreement with UnitedHealthcare that will take effect Aug. 1. ARA will pay $32 million and be required to adopt certain procedures and share information with UnitedHealthcare, whose plan participants will be able to access ARA's dialysis clinics.

Full Story:
Seeking Alpha
7/10/2018

Scientists say they've developed a way to pinpoint risk of developing acute myeloid leukemia years before the onset of symptoms, according to a report in the journal Nature. The researchers sequenced DNA from the blood of 124 patients with AML and 676 people who did not have AML or a related cancer, evaluated data from AML-associated genes, and found certain mutations were more common in those who developed AML.

More Summaries:
leukemia, cancer
7/10/2018

DNA copy-number profiles in circulating cell-free DNA have potential as a biomarker of active disease in melanoma patients, a study shows. The researchers note that "longitudinal analysis of copy-number profiles as an early marker of relapsed disease is warranted."

Full Story:
Clinical Chemistry
7/10/2018

Researchers from MIT's Little Devices Lab have developed small, inexpensive plug-and-play devices that can be modified to detect viral infections or to test blood glucose levels. They also hope to make the Lego-like devices capable of testing for cancer, malaria, Zika virus, Lyme disease and other diseases.

7/9/2018

Modified natural killer cells created from induced pluripotent stem cells have been used to treat ovarian cancer in mice and may lead to immunotherapies for humans that don't have to be tailored to specific patients, a study published in Cell Stem Cell suggests. Researchers modified natural killer cells in a way that is similar to how chimeric antigen receptor T-cells are engineered.

Full Story:
The Scientist online
7/9/2018

A retrospective study in the journal Liver International found that use of direct-acting antivirals may be associated with the reduced number of patients on the waiting list for liver transplant for decompensated hepatitis C virus cirrhosis. Researchers found an increase in HCV patients whose indication for liver transplant was hepatocellular carcinoma during the study period.

More Summaries:
HCV, hepatocellular carcinoma